Evolus, INC. (EOLS) — 10-Q Filings

10-Q Filings (6)

• Evolus Revenue Jumps 14.6% Amid Rising Losses, Cash Burn — Nov 5, 2025 Risk: high
  Evolus, Inc. (EOLS) reported a significant increase in product revenue, reaching $68.967 million for the three months ended September 30, 2025, up from $60.164
• Evolus Q2 Revenue Soars 39%, Net Loss Narrows — Aug 5, 2025 Risk: medium
  Evolus, Inc. reported a significant increase in product revenue for the three months ended June 30, 2025, reaching $62.5 million, up from $45.0 million in the p
• Evolus, Inc. Files Q1 2025 10-Q Report — May 7, 2025 Risk: low
  Evolus, Inc. filed its 10-Q for the period ending March 31, 2025. The company, operating in pharmaceutical preparations, reported financial data for the first q
• Evolus, Inc. Files Q3 2024 10-Q Financial Report — Nov 6, 2024 Risk: medium
  Evolus, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results for the third quarter and the first nine months
• Evolus, Inc. Files Q2 2024 10-Q — Jul 31, 2024 Risk: medium
  Evolus, Inc. filed its 10-Q for the period ending June 30, 2024. The company, based in Newport Beach, CA, operates in the Pharmaceutical Preparations sector. Ke
• Evolus, Inc. Files 10-Q for Period Ending March 31, 2024 — May 7, 2024 Risk: low
  Evolus, Inc. (EOLS) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Evolus, Inc. filed a 10-Q report for the period ending March 31, 2024. The fili

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX